News
Medigene AG: Medigene nimmt an folgenden virtuellen Konferenzen teil
Martinsried/München (28.09.2020) - Die Medigene AG (FWB: MDG1, Prime Standard) wird an folgenden Wissenschafts- und Investoren-Konferenzen teilnehmen. Alle aufgeführten Konferenzen werden
Medigene AG: Medigene participates at upcoming virtual conferences
Martinsried/ Munich (28.09.2020) - Medigene AG (FSE: MDG1, Prime Standard) today announces its participation at the following upcoming scientific and investor conferences. Please note that
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences:
-
Jefferies Virtual Gene Therapy /
Aptinyx Recommences Patient Recruitment in Phase 2 Study of NYX-2925 in Patients with Fibromyalgia
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has
Navidea Biopharmaceuticals to Ring Opening Bell at the New York Stock Exchange
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Aurinia Completes Final Patient Treatment in AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (Aurinia or the Company), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple autoimmune
Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Orient EuroPharma (OEP)
Quantum Genomics to receive up to $19 million in upfront and milestone payments plus double-digit royalties on sales
OEP to receive an exclusive license to develop and commercialize firibastat for
Medigene AG: Strategic measures including restructuring with extension of cash runway and improved EBITDA
Business news for the stock market
Planegg/Martinsried (22.09.2020) - 22 September 2020. Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing
Medigene AG: Strategische Maßnahmen inklusive Restrukturierung mit Verlängerung der Finanzierungsreichweite und verbessertem EBITDA
Unternehmensmitteilung für den Kapitalmarkt
Planegg/Martinsried (22.09.2020) - 22. September 2020. Die Medigene AG (Medigene, FWB: MDG1, Prime Standard), ein Immunonkologie-Unternehmen mit
EnWave unterzeichnet ein Technologiebewertungs- und Lizenzoptionsabkommen mit Extrx OY
Vancouver, British Columbia. 21. September 2020, EnWave Corporation (TSX-V: ENW | FSE: E4U) („EnWave“ oder das „Unternehmen“ - https://www.commodity-tv.com/ondemand/companies/profil/enwave-c
EnWave Signs Technology Evaluation and License Option Agreement with Extrx OY
Vancouver, B.C., September 21st, 2020, EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company” - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) announced
Deciphera Presents Data from QINLOCK™ (Ripretinib) Program in Patients with Gastrointestinal Stromal Tumor at the European Society for Medical Oncology (ESMO) Virtual Congress 2020
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced the presentation of nine month follow-up data from the Company’s Phase 3 INVICTUS study of QINLOCK in patients with fourth-line and
co.don Aktiengesellschaft beschließt Bezugsrechtskapitalerhöhung gegen Bareinlagen aus Genehmigtem Kapital
NICHT ZUR VERBREITUNG, VERÖFFENTLICHUNG ODER WEITERGABE IN ODER INNERHALB DEN USA, AUSTRALIEN, JAPAN ODER KANADA ODER EINER SONSTIGEN JURISDIKTION, IN DER EINE SOLCHE VERÖFFENTLICHUNG REC
New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the data being presented as e-posters at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. These include initial data from
Transgene: Positive Clinical Results for TG4001 and TG6002 and Financial Visibility Secured Until 2022
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial
IMV CEO to Participate at the Vaccines Panel of the Sachs Associates 20th Annual Biotech in Europe Forum
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccine against infectious diseases, today announced that
EnWave Signs Commercial Royalty-Bearing License with Dairy Concepts IRL
Vancouver, B.C., September 15, 2020
EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ), announced
EnWave unterzeichnet kommerzielles Lizenzabkommen mit Dairy Concepts IRL
Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) gab heute bekannt, dass sie eine
Sunesis Pharmaceuticals: Risikoarmes "Peak Play" mit Multibagger-Potenzial
Die Aktie des an der Nasdaq handelnden Krebsforschers Sunesis Pharmaceuticals (WKN: A2QEPW) ist günstiger als jemals zuvor. Wer auf dem aktuellen Kursniveau investiert, bekommt nicht nur Geld
Sangamo Therapeutics Appoints Kenneth Hillan to Its Board of Directors
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Dr. Kenneth Hillan, an accomplished biotechnology executive, to the Company's Board of
Savara Announces Senior Management Changes
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Rob Neville has resigned as the Company’s Chief Executive Officer (CEO) and from the Board of Directors, effective
Clovis Oncology Announces Oral Plenary Session Presentation at International Gynecologic Cancer Society (IGCS) Digital Annual Global Meeting
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that an abstract featuring data from an exploratory analysis of the ARIEL3 clinical study evaluating Rubraca® (rucaparib) as maintenance
Aurinia Pharmaceuticals to Present at Three Upcoming Virtual Investor Conferences
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the senior management team will participate in fireside chats during the following upcoming
Savara to Present at the 22nd Annual H.C. Wainwright Annual Investment Conference Being Held Virtually
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the H.C. Wainwright Annual Investment Conference on Wednesday, September 16
Transgene Announces Upcoming Investor Meetings
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that Management will